StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Earnings

Axsome Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 22, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$259.70M
+51.9% on a year earlier
EPS, Q3 FY2026
-$0.25
-$0.94 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Axsome Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 22, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 2, 2026before the open$259.70M+51.9%-$0.25Release
Q2 FY2026ended Jun 30, 2026Aug 10, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 4, 2026before the open$191.20M+57.4%-$1.26Release
Q4 FY2025ended Dec 31, 2025Feb 23, 2026before the open$196.00M+65.0%-$0.56Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025before the open$171.00M+63.2%-$0.94Release
Q2 FY2025ended Jun 30, 2025Aug 4, 2025before the open$150.00M+72.0%-$0.97Release
Q1 FY2025ended Mar 31, 2025May 5, 2025before the open$121.50M+62.0%-$1.22Release
Q4 FY2024ended Dec 31, 2024Feb 18, 2025before the open$118.80M+66.2%-$1.54Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open$104.80M+81.3%-$1.34Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024before the open$87.20M+86.7%-$1.67Release
Q1 FY2024ended Mar 31, 2024May 6, 2024before the open$75.00M-20.7%-$1.44Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Axsome Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Axsome Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Axsome Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. News
  6. News
  7. Results
  8. Results
  9. News
  10. News
  11. Results
  12. News
  13. Results
  14. News
  15. News

See a number that looks wrong?